Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
67.295
0.225 (0.34%)
Market Cap: 12.83 Bil
Enterprise Value: 12.46 Bil
PE Ratio: 40.30
PB Ratio: 2.37
GF Score: 69/100 
Biomarin Pharmaceutical Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021 / 06:00PM GMT
Release Date Price:
$75.69
(-0.92%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Welcome to the afternoon sessions of the Virtual Vegas BofA Global Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. Aspen Mori from my team is with me as well. And we're thrilled to have BioMarin with us. And speaking on behalf of BioMarin, we have CEO, J.J. Bienaime; and also CFO, Brian Mueller. Welcome, guys.
Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP & CFO
Geoff, thanks for having us.
Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO
Hi, Geoff.
Geoffrey Christopher Meacham;Jean;Jacques Bienaime<
BofA Securities, Research Division - Research Analyst
Rather be in actual Vegas but we'll make this work. So we'll do some questions. But J.J., you want to kick it off with just a couple of high-level takeaways, and then we can get right into it.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers